Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Rating Upgraded by Zacks Research

Ono Pharmaceutical (OTCMKTS:OPHLF) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Ono Pharmaceutical Stock Performance

Shares of OPHLF opened at $15.56 on Monday. The stock has a 50 day moving average price of $14.40 and a two-hundred day moving average price of $14.67. Ono Pharmaceutical has a 52 week low of $10.06 and a 52 week high of $18.67. The firm has a market capitalization of $7.31 billion, a P/E ratio of 15.72 and a beta of 0.34. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.